Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Targacept plans $75M fund raising, as it will develop PhII schizophrenia candidate on its own

This article was originally published in Scrip

Executive Summary

Targacept wants offer at least $75 million in stock to fund its clinical-stage product candidates. The move follows a few weeks after the company said it would be moving forward on its own with schizophrenia candidate TC-5619 after a decision by AstraZeneca to bail on its option for the compound..



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts